Search
All Clinical Trials
A listing of 23124 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
2533 - 2544 of 23124
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT
Recruiting
The goal of this clinical trial is to evaluate whether an AI tool that alerts providers to patients at high 6-year risk of lung cancer based on their chest x-ray images will improve lung cancer screening CT participation. The main question it aims to answer is: Does the AI tool improve lung cancer screening CT participation at 6 months after the baseline outpatient visit
The intervention is an alert to the provider to discuss lung cancer screening CT eligibility, for patients considered at high... Read More
Gender:
ALL
Ages:
Between 50 years and 77 years
Trial Updated:
06/05/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Pediatric cGVHD Symptom Scale
Recruiting
Background:
Some children/adolescents who have had a stem cell transplant live with chronic graft-versus-host-disease (cGVHD). cGVHD is a side effect of the transplant that can cause multiple bothersome symptoms and negatively affect a child/adolescent squality of daily life. The questionnaires that measure thesymptoms caused by cGVHD are designed for adults. Children/adolescents may not describe their symptoms in the same way. The goal of this research is to improve the way we measure how both... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
06/05/2025
Locations: Children's Hospital Colorado (CHCO), Aurora, Colorado +11 locations
Conditions: Graft vs Host Disease
Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth
Recruiting
To evaluate the effect of estradiol with or without a prior gonadotropin releasing hormone analogue on insulin sensitivity and vascular function in transgender females compared to cisgender controls.
Gender:
ALL
Ages:
Between 13 years and 16 years
Trial Updated:
06/05/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Transgenderism, Gender Dysphoria, Insulin Sensitivity
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
Recruiting
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
06/05/2025
Locations: Mog001 50297, Scottsdale, Arizona +76 locations
Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
Recruiting
Double blind, placebo controlled, multicenter randomized trial in pregnant women in the U.S. (N=300) to test the central hypothesis that IV iron in pregnant women with IDA (Hb\<11 g/dL and ferritin\<30 ng/mL) at 13 - 30 weeks will be effective, safe and cost-effective in reducing severe maternal morbidity-as measured by maternal anemia at delivery-and will also improve offspring neurodevelopment.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
06/05/2025
Locations: University of Alabama Medical Center, Birmingham, Alabama +7 locations
Conditions: Iron Deficiency Anemia, Pregnancy
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
Recruiting
To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Brain Metastases
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
Recruiting
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory") are eligible to take part only in Part 1A of the study.
This study is made up of 3 parts: Part 1A (non-randomiz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Boca Raton Clinical Research (BRCR) Global, Plantation, Florida +122 locations
Conditions: Follicular Lymphoma (FL)
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study
Recruiting
Background:
Some people have a condition in which the wall (septum) that separates the two main pumping chambers of the heart is too thick. This thick septum causes a condition called "left ventricular outflow tract obstruction" (LVOTO), which reduces blood flow out of the heart. LVOTO can cause serious heart disease; symptoms may include shortness of breath, chest pain, heart failure, or death. Researchers want to find better ways to treat LVOTO.
Objective:
To test a new procedure where exce... Read More
Gender:
ALL
Ages:
Between 21 years and 99 years
Trial Updated:
06/05/2025
Locations: Emory University Hospital, Atlanta, Georgia +1 locations
Conditions: Hypertrophic Cardiomyopathy, Left Ventricular Septal Hypertrophy, Mitral Valve Disease, Aortic Valve Stenosis
Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents
Recruiting
Background:
Hypereosinophilic syndrome (HES) is a blood disorder that causes high levels of white blood cells called eosinophils. HES can damage the lungs and airways, intestines, skin, and other organs. The current primary treatment for HES can cause serious side effects. Secondary treatments do not work in all people.
Objective:
To test an approved drug (dupilumab), combined with other drugs, in people with HES.
Eligibility:
People aged 18 years and older who take drugs (mepolizumab, resl... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/05/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hypereosinophilic Syndrome
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Recruiting
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the metastatic sett... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Usc Norris Comprehensive Cancer Center, Los Angeles, California +133 locations
Conditions: PD-L1-positive Metastatic NSCLC
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
Recruiting
The ReMATCH Study is a prospective, single arm, open label, multi-center, study utilizing the FARAPULSE PFA System, including the FARAWAVE and FARAPOINT PFA Catheters.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Arrhythmia Research Group-Research Facility, Jonesboro, Arkansas
Conditions: Persistent Atrial Fibrillation
Leg Heating in Pregnant Women With Obesity
Recruiting
Obesity is a major risk factor for hypertensive disorders of pregnancy (HDP). The underlying mechanisms are largely unclear, but maternal vascular endothelial dysfunction is likely involved. Endothelial dysfunction in HDP could be attributed to 1) alterations in the L-arginine/nitric oxide (NO) pathway, and 2) an increase in endothelin-1 (ET-1). Additionally, augmented sympathetic vasoconstriction may also contribute to HDP. Chronic (repeated) whole-body heat exposure has been shown to increase... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
06/05/2025
Locations: UT Southwestern Medical Center; Institute for Exercise and Environmental Medicine, Dallas, Texas
Conditions: High-risk Pregnancy
2533 - 2544 of 23124